While inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were among the first treatments approved for Alzheimer’s disease (AD), with clinical trials consistently documenting modest but real cognitive and functional improvements, the focus turned to Aβ- and tau-directed treatment strategies. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.